Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 4/20 | 0.44 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.40 |
| ▸ | WDR5 | P61964 | 2/20 | 0.40 |
| ▸ | MMP13 | P45452 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16135599 | 0.92 | MT-CO2 (0.41) | PPARGCXCR3P2RX7WDR5MAPK1 | |
| SCHEMBL16135540 | 0.89 | PDE4A (0.46) | ALDH1A1WDR5MMP13MAPK1 | |
| SCHEMBL16135557 | 0.89 | PDE4A (0.48) | ALDH1A1WDR5MAPK1GSK3B | |
| SCHEMBL21014157 | 0.89 | WDR5 (0.38) | PPARGCXCR3P2RX7WDR5MMP13 | |
| SCHEMBL16135708 | 0.88 | P2RX7 (0.48) | P2RX7WDR5 | |
| SCHEMBL16135630 | 0.88 | MAPK8 (0.44) | CXCR3P2RX7WDR5 | |
| SCHEMBL16135583 | 0.87 | PDE4A (0.41) | ALDH1A1WDR5GSK3BGRM4 | |
| SCHEMBL16135705 | 0.87 | PDE4A (0.42) | S1PR3WDR5 | |
| SCHEMBL16135584 | 0.86 | WDR5 (0.46) | ALDH1A1WDR5MAPK1GSK3B | |
| SCHEMBL16135592 | 0.86 | WDR5 (0.46) | ALDH1A1WDR5MAPK1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970124-B1 | MITOCHONDRIAL ALDEHYDE DEHYDROGENASE-2 MODULATORS AND METHODS OF USE THEREOF | UNIV LELAND STANFORD JUNIOR (US) | 2019-05-22 | — | — | EP | disclosed |
| US-10227304-B2 | Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2019-03-12 | — | — | US | disclosed |
| US-20170320828-A1 | Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2017-11-09 | — | — | US | disclosed |
| US-20170320828-A1 | Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2017-11-09 | — | — | US | disclosed |
| US-9670162-B2 | Mitochondrial aldehyde dehyrogenase-2 modulators and methods of use thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670162-B2 | Mitochondrial aldehyde dehyrogenase-2 modulators and methods of use thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160107996-A1 | Mitochondrial Aldehyde Dehyrogenase-2 Modulators and Methods of Use Thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2016-04-21 | — | — | US | disclosed |
| US-20160107996-A1 | Mitochondrial Aldehyde Dehyrogenase-2 Modulators and Methods of Use Thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2016-04-21 | — | — | US | disclosed |
| WO-2014160185-A2 | MITOCHONDRIAL ALDEHYDE DEHYDROGENASE-2 MODULATORS AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160107996-A1 | Mitochondrial Aldehyde Dehyrogenase-2 Modulators and Methods of Use Thereof | ALDH2, ALDH5A1, SHMT2 | PPARG 519/4885CXCR3 4825/4885P2RX7 4468/4885 |
| US-20170320828-A1 | Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof | ALDH2, ALDH5A1, DLD | PPARG 493/4885CXCR3 4814/4885P2RX7 4062/4885 |
| US-10227304-B2 | Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof | ALDH2, ALDH5A1, DLD | PPARG 493/4885CXCR3 4814/4885P2RX7 4062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.